Clinical Trial

Long-term Effect of Dupilumab in N-ERD

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated July 8, 2025 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This prospective observational study investigates the long-term effects of Dupilumab in patients with NSAID-exacerbated respiratory disease (N-ERD). The study assesses changes in ASA tolerance, clinical parameters, inflammatory biomarkers, quality of life, and nasal microbiome during ongoing treatment with Dupilumab. All participants are receiving Dupilumab as part of standard clinical care.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-02.
Trial Details
NCT Number NCT07049978
Lead Sponsor Medical University of Vienna
Conditions NSAID-Induced Asthma, NSAIDs Hypersensitivity, Chronic Rhinosinusitis (CRS), Asthma Bronchiale, Nasal Polyposis
Enrollment 30 participants
Start Date 2025-07-01
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-07-08